Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib (JAK1 Inhibitor): Atopic Dermatitis
- Braftovi® (encorafinib) + Erbitux® (cetuximab): 1st line BRAF-mutant Metastatic Colorectal Cancer
- Braftovi® (encorafinib) + Mektovi® (binimetinib) + Keytruda® (pembrolizumab): BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
- COVID-19 Vaccine: COVID-19 Infection (in collaboration with BioNTech)
- Fidanacogene elaparvovec (PF-06838435) (Gene Therapy, coagulation factor IX): Hemophilia
- Fordadistrogene movaparvovec (PF-06939926) (Gene Therapy): Duchenne Muscular Dystrophy
- Giroctocogene fitelparvovec (PF-07055480) (Gene Therapy, coagulation factor VIII): Hemophilia
- Marstacimab (PF-06741086) (Tissue Factor Pathway Inhibitor): Hemophilia
- Prophylactic Vaccine: Clostridioides difficile infection
- Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal infections (adult, pediatric)
- Prophylactic Vaccine: Meningococcal Infections (adolescent and young adults)
- Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
- Relugolix combination: Uterine Fibroids, Endometriosis
- Ritlecitinib (JAK3/TEC Inhibitor): Alopecia Areata
- Sasanlimab (PF-06801591) + BCG: Non-Muscle-Invasive Bladder Cancer
- Somatrogon (PF-06836922): Growth Hormone Deficiency (adult, pediatric)
- Talzenna® (talazoparib) + Xtandi® (enzalutamide): 1st Line Metastatic Castration-Resistant Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis; Cancer Pain
- Xtandi® (enzalutamide): Non-metastatic High-Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of May 4, 2021
- Discovery Projects
- 30Phase 1
- 38Phase 2
- 22Phase 3
- 10Registration
- Total100
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-06482077 Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (adult) (BREAKTHROUGH, FAST TRACK - U.S.; E.U.)
Project advanced | Registration | New Molecular Entity | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S.; E.U.) | Registration | New Molecular Entity | Vaccine |
TicoVac Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Tick-borne encephalitis (TBE) (U.S.)
Project advanced | Registration | New Molecular Entity | Vaccine |
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Primary Clostridioides difficile infection (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (pediatric) (BREAKTHROUGH, FAST TRACK) | Phase 3 | Product Enhancement | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (adolescent and young adults) | Phase 3 | New Molecular Entity | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (maternal) (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive Group B Streptococcus Infection (maternal) (FAST TRACK) | Phase 2 | New Molecular Entity | Vaccine |
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants and children) | Phase 2 | New Molecular Entity | Vaccine |
PF-07307405 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Lyme disease (FAST TRACK) | Phase 2 | New Molecular Entity | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (maternal)
Project advanced | Phase 2 | Product Enhancement | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (children 2 to 11 years of age)
Project advanced | Phase 2 | Product Enhancement | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (infants 6 months to <24 months)
Project advanced | Phase 2 | Product Enhancement | Vaccine |
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (E.U.)
Project advanced | Registration | Product Enhancement | Small Molecule |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Metastatic Castration Sensitive Prostate Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 kinase inhibitor | ER+/HER2+ Metastatic Breast Cancer(PATINA) | Phase 3 | Product Enhancement | Small Molecule |
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti-PD-1 | Non-Muscle-Invasive Bladder Cancer (Biologic) | Phase 3 | New Molecular Entity | Biologic |
